FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours nor reenenee | . 0 5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Peltz Stuart Walter (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT (Street) SOUTH PLAINFIELD NJ 07080 | | | | | | | Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT] June of Earliest Transaction (Month/Day/Year) 1/05/2023 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) CHIEF EXECUTIVE OFFICER 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting | | | | | |
|---|--|--|---|--|---|---|---|--------------|---------------------------------------|--|-------------------------|---|-----------|------------------------|--|--|--------------------------------------|--|---------------------------------------|--|
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | Person | | | | | |
| | | Та | ble I - Non | n-Deriv | /ativ | /e Se | ecurities | s Ac | quired, | Dis | posed o | f, or B | enef | icially | Owned | | | | | |
| 1 | | | | 2. Transaction Date (Month/Day/Year) | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Code (Instr. | | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 | | | | Beneficia Owned Fo | s For ally (D) ollowing (I) (| | : Direct II Indirect E str. 4) | 7. Nature of ndirect Beneficial Ownership | | |
| | | | | | | | | | | v | Amount | (A (D | or | Price | Reported Transacti (Instr. 3 a | on(s) | | , | Instr. 4) | |
| Common Stock 01/0 | | | | | | /2023 | | | Α | | 53,000 ⁽¹⁾ A | | A | \$ <mark>0</mark> | 173 | 173,485 | | D | | |
| Common Stock 0 | | | | 01/0: | 5/2023 | | | | A | | 18,000 |)(1) | A | \$0 | 56,8 | 830(2) | | | By Spouse | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Da if any (Month/Day/\) | ate, Tr | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Ex Expiration (Month/Da | Date | | 7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4) | | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficia Owned Following Reported Transaction | s Illy | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | C | ode | v | (A) | (D) | Date Exercisab | | xpiration ate | Title | or Nur | ount nber Shares | | (Instr. 4) | G11(3) | | | |
| Stock Option (Right to Buy) | \$39.42 | 01/05/2023 | | | A | | 132,500 | | (3) | 0 | 1/04/2033 | Commo Stock | 13 | 2,500 | \$0 | 132,50 | 00 | D | | |
| Stock Option (Right to Buy) | \$39.42 | 01/05/2023 | | | A | | 45,000 | | (3) | 0 | 1/04/2033 | Commo Stock | 45 | 5,000 | \$0 | 45,00 | 0 | Ι | By Spouse | |

Explanation of Responses:

- 1. Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024.
- 2. Includes 293 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2022 and 298 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2022.
- 3. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

/s/ Avraham S. Adler, Attorneyin-Fact 01/09/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.